Fund moves

Pfizer (PFE): Deerfield Management Company, L.P. opened a new position $84.8M

Deerfield Management Company, L.P. opened a new position in Pfizer, per its Q1 2025 13F.

3.35M
Shares reported
1.9%
Disclosed portfolio weight
$84.8M
Reported value
Holdings as of
Mar 31, 2025
Filed
May 15, 2025

What stands out in this filing

  • A new position in Q1 2025: 3,347,296 shares, none in the manager's Q4 2024 filing.
  • Reported at $84.8M, 1.91% of the portfolio value in this 13F filing.
  • 13 other tracked managers reported the same kind of change for Q1 2025.

Calculated by OQRO from this filing and the public records it holds. Facts about the record, not a reason for the trade and not a signal.

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Feb 25, 2025CongressDisclosed purchase of PFE — reported range $15,001 - $50,000
  2. Mar 3, 2025CongressDisclosed purchase of PFE — reported range $1,001 - $15,000
  3. Mar 10, 2025CongressDisclosed sale of PFE — reported range $1,001 - $15,000
  4. Mar 31, 2025Congress · 1 personMembers of Congress: 2 sales
  5. Apr 8, 2025CongressDisclosed sale of PFE — reported range $15,001 - $50,000
  6. Apr 11, 2025CongressDisclosed sale of PFE — reported range $15,001 - $50,000
  7. Apr 21, 2025CongressDisclosed sale of PFE — reported range $1,001 - $15,000
  8. Apr 23, 2025FDAFDA drug approval: Ibrance
  9. Apr 23, 2025FDAFDA drug approval: Ibrance
  10. Apr 29, 2025CongressDisclosed purchase of PFE — reported range $1,001 - $15,000
  11. May 15, 2025CongressDisclosed purchase of PFE — reported range $15,001 - $50,000

What came next

  1. May 28, 2025FDARecall: DOBUTamine Injection, USP, 250 mg/20 mL (12.5 mg/mL), 20 mL per Single-dose Vial, carton of 10 Fliptop Vials, Rx only, For Intravenous Use Only, Made in Italy,…
  2. May 30, 2025CongressDisclosed purchase of PFE — reported range $1,001 - $15,000
  3. Jun 3, 2025Congress · 2 peopleMembers of Congress: 2 sales
  4. Jun 12, 2025FDAFDA drug approval: Talzenna
  5. Jun 12, 2025FDAFDA drug approval: Talzenna
  6. Jul 10, 2025FDAFDA drug approval: Elrexfio
  7. Jul 10, 2025FDARecall: Bicillin L-A (penicllin G benzathine injectable suspension), 1,200,000 units per 2 mL, 2 mL-vial, Rx Only, Distributed by Pfizer Inc., New York, NY 10001. Made…
  8. Jul 10, 2025FDARecall: Bicillin L-A (penicillin G benzathine injectable suspension), 2,400,000 units per 4 mL, 4ml-vial, Rx Only, Distributed by Pfizer Inc., New York, NY 10001, Made…
  9. Jul 16, 2025CongressDisclosed purchase of PFE — reported range $1,001 - $15,000
  10. Jul 29, 2025FDARecall: Levoxyl (levothyroxine sodium tablets, USP), 50 mcg, 100-count bottle, Rx only, Distributed by: Pfizer Inc., New York, NY 10017, Made in Austria, NDC 60793-851…
  11. Aug 4, 2025FDARecall: Vial Label: Epinephrine Injection, USP, 1mg/10mL (0.1 mg/mL), Rx only, Distributed by Hospira, Inc., Lake Forest, IL 60045, USA. NDC 0409-4933-05. Case: NDC 04…
  12. Aug 4, 2025FDARecall: Vial Label: 8.4% Sodium Bicarbonate Injection, USP, 50mEq/50 mL (1 mEq/mL), Rx only, Hospira, Inc., Lake Forest, IL 60045, USA, NDC 0409-6637-24. Case NDC: 004…
  13. Aug 4, 2025CongressDisclosed sale of PFE — reported range $1,001 - $15,000
  14. Aug 5, 2025CongressDisclosed partial sale of PFE — reported range $1,001 - $15,000
  15. Aug 25, 2025Layoff notice · BothellLayoff notice filed in WA: 100 employees
  16. Sep 11, 2025FDAFDA drug approval: Potassium Phosphates
View the official recordSEC Form 13F-HR

How to read SEC Form 13F-HR

Form 13F is the quarterly report in which investment managers that oversee $100 million or more list the US-listed stocks and some other securities they held on the last day of the quarter.

Full guide: What is an SEC Form 13F?

What else is on file for Pfizer

For Pfizer, OQRO holds 1 fund holdings report (13F) and 1 federal contract award dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its PFE page.

How this filing works

Explore the data

Common questions

What does this filing report about Pfizer (PFE) stock?

Deerfield Management Company, L.P. opened a new position in Pfizer, per its Q1 2025 13F. 3.35M shares reported, 1.9% of disclosed portfolio.

When did it happen, and when was it made public?

Holdings as of: Mar 31, 2025. Filed: May 15, 2025.

What stands out in this filing?

A new position in Q1 2025: 3,347,296 shares, none in the manager's Q4 2024 filing. Reported at $84.8M, 1.91% of the portfolio value in this 13F filing. 13 other tracked managers reported the same kind of change for Q1 2025.

Is this a trade made on a known date?

No. A holdings report is a picture of the portfolio on the last day of the quarter. It shows what was held on that day, not the day or the price at which anything was bought or sold.

Where does this information come from?

From the SEC Form 13F-HR, a public record. The link to the official record is on this page, and OQRO copies its figures without changing them.

What else has been disclosed about Pfizer recently?

For Pfizer, OQRO holds 1 fund holdings report (13F) and 1 federal contract award dated in the last 90 days. They are listed on the PFE page.

Does this mean PFE stock is a buy or a sell?

No. This page describes one public filing. A filing does not say why someone traded and is not a forecast, so OQRO gives no recommendation.

Is OQRO free?

Yes. Every page of OQRO is free with an account, which takes a minute with Google and needs no card. Only the AI assistant is paid.

Other disclosures at Pfizer

Everything OQRO holds on this company is on its PFE page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

OQRO is free for everyone. No card, no trial

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data